Tier 2 — strong

The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial

Li M, Liu Y, Qiu Y, Zhang J, Zhang Y, Zhao Y, Jia Q, Li J
Psychiatry research 2021 300:113899

Bibliography

PubMed
PMID 33812218
DOI
10.1016/j.psychres.2021.113899
Funding
Funding was not established from the accessible source; this is not a declaration of no funding.
Competing interests
A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.

Study snapshot

DesignDouble-blind placebo-controlled randomized adjunctive trial
ModelHuman participants; see population
Sample65 enrolled; 49 completed
InterventionBerberine 900 mg/day added to antipsychotic treatment versus placebo
Duration8 weeks
EndpointsMetabolic or symptom outcomes; Inflammatory markers; Tolerability

What the study showed, in plain terms

Adjunctive treatment improved selected cholesterol and insulin-resistance measures in schizophrenia.

Key findings

  • Adjunctive treatment improved selected cholesterol and insulin-resistance measures in schizophrenia.

What this study can and cannot tell us

Attrition and small sample; the 65-person cohort appears in companion reports and must not be counted repeatedly.

Source detail: indexed abstract and bibliographic record; unavailable methods or disclosures are identified rather than assumed.

Related papers in the corpus

Tier 4
Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin
Qiu Y et al. · Asian journal of psychiatry · 2022
Tier 2
Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia
Li M et al. · European archives of psychiatry and clinical neuroscience · 2022
Tier 2
Berberine improves negative symptoms and cognitive function in patients with chronic schizophrenia via anti-inflammatory effect: a randomized clinical trial
Pu Z et al. · Chinese medicine · 2023
Tier 2
Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial
Chan M et al. · Psychiatry and clinical neurosciences · 2022
Tier 2
Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson's Disease Patients
Li J et al. · Contrast media & molecular imaging · 2022

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology